H.C. Wainwright lowered the firm’s price target on Harmony Biosciences (HRMY) to $70 from $75 and keeps a Buy rating on the shares following the Q4 report. The firm says Wakix continues to drive growth as the company’s pipeline advances in 2025. However, the firm removed potential revenue from Wakix in idiopathic hypersomnia.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences price target raised to $33 from $31 at BofA
- Cautious Outlook: Sell Rating for Harmony Biosciences Due to Pipeline Concerns and Generic Competition Risks
- Harmony Biosciences Reports Strong 2024 Financial Results
- Harmony Biosciences files automatic mixed securities shelf
- Harmony Biosciences Holdings: Strong Financial Performance and Strategic Settlements Drive Buy Rating